Subsequent treatment with the specific SIRT1 activator Cay10591 for IBD in lamina propria mononuclear cells decreased the NF-κB activation and inhibited the synthesis of inflammatory cytokines, whereas treatment with the SIRT1 inhibitor Ex-527 increased the release of interferon (IFN)-γ (82). Here, SIRT1 is linked to inflammatory bowel disease.